AccessibilityHelpAbout Us
SomnoMed logo

SomnoMed(OTC) SOMNF

Market Cap$52.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+697%
5 Year-86%
1 Year-45%
1 Month-47%
$0.24
+0.00%
+0.00Today
SomnoMed last closing stock price
MetricPriceDate
Last closeUSD 0.242026-09-11
SomnoMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-46.65%USD 0.452026-04-29
1 month-46.65%USD 0.452026-04-29
3 month-46.65%USD 0.452026-04-29
Year to date-53.59%USD 0.512025-12-31
1 year-45.21%USD 0.442025-08-15
3 year-54.19%USD 0.522023-08-22
5 year-86.11%USD 1.722021-09-10
Since inception+696.5%USD 0.032007-11-12

SomnoMed Financials at a Glance

Market Cap

$52.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$225.93M

Net Income (TTM)

-A$6.10M

EPS (TTM)

-$0.01

P/E Ratio

-27.78

Dividend

$0.00

Beta (Volatility)

0.07 (Low)

Price

$0.24

Volume

1,700

Open

$0.24

Previous Close

$0.24

Daily Range

$0.24 - $0.24

52-Week Range

$0.24 - $0.51

Estimated Earnings Date

Feb 26, 2026

SOMNF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SomnoMed

SomnoMed Limited is a healthcare company specializing in the production and sale of oral devices for the treatment of sleep-related disorders. The company operates primarily in the Asia Pacific region, North America, and Europe, offering innovative solutions for obstructive sleep apnea and other related conditions.

Products and Services
  • SomnoDent Avant, Classic, Flex, and Fusion for obstructive sleep apnea
  • SomMorning Repositioner to restore mandible position
  • SomTabs cleaning tablets for oral appliances
Growth Outlook
  • Increasing global awareness of sleep disorders drives demand for products
  • Expansion into new markets enhances revenue potential
  • Innovative product development supports competitive advantage
Financial Highlights
  • Recent quarterly revenue of 53.74 million AUD shows strong market presence
  • Trailing twelve months gross profit margin at 54.48% indicates operational efficiency
  • Cash flow from operations of 4.12 million AUD reflects solid liquidity position
SomnoMed Limited has established itself as a key player in the medical devices sector, focusing on oral treatments for sleep disorders. The company's diverse product range, including various SomnoDent models and supportive devices, caters to a growing market of patients seeking effective solutions for sleep apnea. The growth outlook remains positive, driven by increasing awareness of sleep-related health issues and the company's strategic expansion into new markets. Innovative product development continues to enhance SomnoMed's competitive edge, positioning the company favorably for future growth. Financially, SomnoMed has demonstrated resilience, with a recent quarterly revenue of 53.74 million AUD, showcasing its strong market presence. The trailing twelve months gross profit margin of 54.48% indicates effective cost management and operational efficiency. Additionally, a cash flow from operations of 4.12 million AUD highlights a solid liquidity position, providing the company with the necessary resources to invest in future growth initiatives.
AI Generated • Sep 1, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Amrita Blickstead, MBA; Karen Borg

Website

www.somnomed.com

Headquarters

Crows Nest, NSW 2065, AU

SOMNF Financials

Key Financial Metrics (TTM)

Gross Margin

54.48%

Operating Margin

0.85%

Net Income Margin

-2.31%

Return on Equity

-5.44%

Return on Capital

1.85%

Return on Assets

-3.53%

Earnings Yield

-3.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$52.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

219.77M

Volume

1.70K

Avg. Volume

26.984

Financials (TTM)

Gross Profit

A$129.08M

Operating Income

A$4.59M

EBITDA

A$8.04M

Operating Cash Flow

A$16.05M

Capital Expenditure

-A$5.68M

Free Cash Flow

A$10.37M

Cash & ST Invst.

A$17.16M

Total Debt

A$5.45M

SomnoMed Performance Analysis

SomnoMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 56,248,9716.9%
20242024-06-30AUD 60,065,8226.8%
20252025-06-30AUD 72,206,28420.2%
20262026-06-30AUD 77,609,5117.5%
SomnoMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3115.4%
Q42025-06-307.6%
Q22025-12-315.0%
Q42026-06-30-11.5%
SomnoMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0567.3%
20242024-06-30AUD -0.0731.2%
20252025-06-30AUD -0.01-84.1%
20262026-06-30AUD -0.01-21.7%
SomnoMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3198.2%
Q42025-06-30-1644.4%
Q22025-12-31122.9%
Q42026-06-30-536.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$53.74M

+15.5%

Gross Profit

A$27.97M

+15.6%

Gross Margin

52.05%

N/A

Market Cap

$52.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$113.91K

N/A

Employees

461

N/A

Net Income

-A$3.44M

+41.7%

EBITDA

A$801.87K

+149.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$17.16M

+6.1%

Total Debt

A$5.45M

-18.9%

Accounts Receivable

A$11.61M

+46.5%

Inventory

A$7.35M

+16.9%

Long Term Debt

A$3.20M

-22.2%

Short Term Debt

A$2.25M

-13.7%

Return on Assets

-3.53%

N/A

Return on Invested Capital

1.89%

N/A

Free Cash Flow

A$3.24M

+223.6%

Operating Cash Flow

A$4.13M

+334.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AURXNuo Therapeutics, Inc.
$1.30+8.33%
GRUSFGrown Rogue International Inc.
$0.42-2.74%
CORBFGlobal Cord Blood Corporation
$0.95-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About SOMNF

What is the current price of SomnoMed?

SomnoMed is trading at $0.24 per share.

What is the 52-week range for SomnoMed?

Over the past 52 weeks, SomnoMed has traded between $0.24 and $0.51.

How much debt does SomnoMed have?

As of the most recent reporting period, SomnoMed reported total debt of A$3.78M.

How much cash does SomnoMed have on hand?

SomnoMed reported A$11.91M in cash and cash equivalents in its most recent financial results.

What is SomnoMed’s dividend yield?

SomnoMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services